Development of a Genotype 325–Specific proCPU/TAFI ELISA

Objective—A Thr/Ile polymorphism at position 325 in the coding region of proCPU has been reported. Immunological assays, fully characterized (including genotype dependency), are required for the quantitation of proCPU levels. Methods and Results—We have generated a panel of monoclonal antibodies against human, plasma-derived proCPU. Two combinations exhibiting distinct reactivities were selected for measurement of proCPU in plasma. T12D11/T28G6-HRP yielded values of 10.1±3.1 &mgr;g/mL (mean±SD, n=86; normal donors), and T32F6/T9G12-HRP yielded values of 5.4±3.0 &mgr;g/mL. Grouping according to the 325 genotype demonstrated that T12D11/T28G6-HRP was independent to this polymorphism whereas T32F6/T9G12-HRP revealed a complete lack of reactivity with the Ile/Ile genotype (ie, 0.0±0.0, 4.2±1.7, and 7.3±2.9 &mgr;g/mL for the Ile/Ile, Ile/Thr, and Thr/Thr isoforms, respectively). Commercially available antigen assays appeared to be partially dependent on the 325 genotype (eg, 44±8.9% and 100±30% for the Ile/Ile and Thr/Thr isoforms, respectively). Conclusions—Our data demonstrate that great care should be taken when evaluating proCPU antigen values as a putative causative agent or as a diagnostic risk marker for cardiovascular events.

[1]  J. Enghild,et al.  Activated Human Plasma Carboxypeptidase B Is Retained in the Blood by Binding to α2-Macroglobulin and Pregnancy Zone Protein* , 1996, The Journal of Biological Chemistry.

[2]  M. Potter,et al.  Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane) , 1969, Nature.

[3]  M. Boffa,et al.  Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). , 1999, Biochemistry.

[4]  L. Tiret,et al.  Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. , 2001, Blood.

[5]  S. Scharpe,et al.  Characterisation of a Carboxypeptidase in Human Serum Distinct from Carboxypeptidase N , 1989, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[6]  P. Nakane,et al.  PEROXIDASE-LABELED ANTIBODY A NEW METHOD OF CONJUGATION , 1974, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  M. Boffa,et al.  Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties* , 1998, The Journal of Biological Chemistry.

[8]  D. Drayna,et al.  Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. , 1991, The Journal of biological chemistry.

[9]  G. Vanhoof,et al.  The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11. , 1996, Genomics.

[10]  F. Goossens,et al.  Proteolytic activation of purified human procarboxypeptidase U. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[11]  P. Morange,et al.  Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[12]  V. Kunzmann,et al.  A novel , possibly functional , single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor ( TAFI ) gene is also associated with TAFI levels , 2022 .

[13]  M. Margaglione,et al.  Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[14]  A. Evans,et al.  Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence , 2003, Thrombosis and Haemostasis.

[15]  F. Goossens,et al.  Fast Homogeneous Assay for Plasma Procarboxypeptidase U , 2001, Clinical chemistry and laboratory medicine.

[16]  P. Dawson,et al.  Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. , 2002, Biochemistry.

[17]  A. Hamsten,et al.  Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease , 2000, Thrombosis and Haemostasis.

[18]  P. Morange,et al.  Plasma TAFI Antigen Variations in Healthy Subjects , 2000, Thrombosis and Haemostasis.

[19]  H. Neels,et al.  Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. , 1999, Clinical chemistry.

[20]  M. Boffa,et al.  A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[21]  S. Leitman,et al.  Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. , 2002, Blood.

[22]  P. Reitsma,et al.  Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. , 2001, Haematologica.

[23]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[24]  M. Nagashima,et al.  Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms , 1998, Thrombosis and Haemostasis.

[25]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[26]  R. Verkerk,et al.  Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma , 2001, Thrombosis and Haemostasis.

[27]  C. Jenkin,et al.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. , 1978, Immunochemistry.

[28]  C. Milstein,et al.  Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.

[29]  M. Boffa,et al.  Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor* , 2000, The Journal of Biological Chemistry.

[30]  P. A. von dem Borne,et al.  Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation , 1998, Thrombosis and Haemostasis.

[31]  C. Milstein,et al.  [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .

[32]  M. Nesheim,et al.  Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*) , 1995, The Journal of Biological Chemistry.

[33]  M. Boffa,et al.  Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme* , 2002, The Journal of Biological Chemistry.

[34]  A. Evans,et al.  Association between TAFI antigen and Ala l47Thr polymorphism of the TAFI gene and the angina pectoris incidence , 2003 .